SMAD3 and hepatocellular carcinoma: In the contrast, the HCC-1T, 3T, and 4T showed reduced TGF-β signaling and diminished SMAD3 activation, while exhibiting activation of NR1I3, NR1I2, and HNF4A, consistent with the results from scRNA-HCC cohort (Fig. S8D-S8F).